Arvinas has been granted a patent for bifunctional compounds that target tau protein for degradation, potentially treating diseases caused by tau accumulation. The compounds contain a VHL or cereblon ligand to bind to E3 ubiquitin ligase and a moiety to bind tau protein. GlobalData’s report on Arvinas gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Arvinas Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Arvinas, Cancer treatment biomarkers was a key innovation area identified from patents. Arvinas's grant share as of February 2024 was 21%. Grant share is based on the ratio of number of grants to total number of patents.

Bifunctional compounds for modulating tau protein

Source: United States Patent and Trademark Office (USPTO). Credit: Arvinas Inc

A recently granted patent (Publication Number: US11912699B2) discloses a compound that shows promising results in the degradation of Tau protein, a key factor in neurodegenerative diseases like Alzheimer's. The compound, when tested on CHOK1 Tau P301 L cells, demonstrated Tau protein degradation of over 50% after 48 hours of treatment, highlighting its potential therapeutic value in combating such conditions. Additionally, the compound also showed efficacy in an in vivo tauopathy mouse model, further supporting its role in targeting pathologic tau aggregates.

Moreover, the patent also covers a pharmaceutical composition containing the compound along with a pharmaceutically acceptable carrier. This composition may further include an additional bioactive agent, such as anti-neurodegenerative agents or P-gp inhibitors like Amiodarone, Azithromycin, and Verapamil. The inclusion of these agents aims to enhance the therapeutic effects of the compound in treating Alzheimer's disease. The patent also outlines a method for treating Alzheimer's disease by administering the disclosed compounds and their pharmaceutically acceptable salts to individuals in need of such treatment, offering a potential new avenue in the fight against this debilitating condition.

To know more about GlobalData’s detailed insights on Arvinas, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies